Long-term metastatic melanoma survival dramatically improves on immunotherapy
September 17, 2024
September 17, 2024
ITHACA, New York, Sept. 17 -- Cornell University issued the following news:
Long-term data from a landmark international trial show about half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors survive cancer-free for 10 years or more, according to a new report from Weill Cornell Medicine and Dana-Farber Cancer Center investigators and their colleagues.
The 10-year follow-up study, published Sept. 15 in the New England Journa . . .
Long-term data from a landmark international trial show about half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors survive cancer-free for 10 years or more, according to a new report from Weill Cornell Medicine and Dana-Farber Cancer Center investigators and their colleagues.
The 10-year follow-up study, published Sept. 15 in the New England Journa . . .